Phase 1Completed

TMC435-TiDP16-C112 - Interaction Trial With Antidepressants

A Phase I, Open-label, Randomized, 3-way Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Escitalopram at Steady-state

Sponsor
Tibotec Pharmaceuticals, Ireland (Industry)
Enrollment
20 enrolled
Conditions
Hepatitis C Virus
Interventions
TMC435; Escitalopram; TMC435 + Escitalopram
Ages
adults
Registry
NCT01090700

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 150mg q.d. (once a day) on the steady-state pharmacokinetics of escitalopram 10 mg q.d., and vice versa. Steady state is a term which means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (pk) means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.

Primary outcomes

  • To investigate the effect of stable blood levels of TMC 435 given 150 mg q.d. on the stable blood levels of escitalopram given 10 mg q.d. in healthy participants and vica versa.

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered